KALA BIO, Inc. (KALA) Q1 2021 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning and welcome to Kala Pharmaceuticals' first quarter 2021 financial results conference call. At this time, all participants are in listen-only mode. Following management prepared remarks, a Q&A session will be held as a reminder. This call is being recorded. I would now like to turn the call over to Nairanjan Kamraswanan, Senior Vice President of Strategy for Kala Pharmaceuticals. Please proceed. Thank you, Operator, and thank you all for participating in today's call. Mark Iwiki, Chairman, President, and Chief Executive Officer, Todd Bazemore, Chief Operating Officer, Mary Remeth, Chief Financial Officer, and Kim Brazel, our Chief Medical Officer. Today's call is being webcast live. The webcast link can be found in the Investors and Media section of our website at www.calarx.com. During this call, we will be referring to non-GAAP financial measures which are not prepared in accordance with generally accepted accounting principles. Reconciliation of the non-GAAP financial measures to the most directly comparable GAAP measures is available in our press release issued today, which can also be found on our website. On this call, we will make certain comments about CALA's future expectations, plans, and prospects that are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements will include statements regarding the potential market and commercial launch plans for ISUVIS, observations associated with our commercialization of ISUVIS and INVELTIS, and the sufficiency of our cash resources. These and other forward-looking statements are based on the beliefs and expectations of management as of this conference call. Our actual results may differ materially from our expectations. The company undertakes n...